Viracta Therapeutics, Inc. (VIRX)
Largest Insider Buys in Sector
VIRX Stock Price History Chart
VIRX Stock Performance
About Viracta Therapeutics, Inc.
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
Insider Activity of Viracta Therapeutics, Inc.
Over the last 12 months, insiders at Viracta Therapeutics, Inc. have bought $49,362 and sold $9,446 worth of Viracta Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Viracta Therapeutics, Inc. have bought $532,675 and sold $134,323 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Rothera Mark (President and CEO) — $98,723.
The last purchase of 47,906 shares for transaction amount of $23,627 was made by Rothera Mark (President and CEO) on 2023‑12‑01.
List of Insider Buy and Sell Transactions, Viracta Therapeutics, Inc.
| 2024-02-27 | Sale | Chevallard Daniel R. | CFO and COO | 3,405 0.0083% | $0.73 | $2,493 | +8.77% | |
| 2023-12-01 | Rothera Mark | President and CEO | 47,906 0.1301% | $0.49 | $23,627 | +47.32% | ||
| 2023-11-30 | Rothera Mark | President and CEO | 52,094 0.1374% | $0.49 | $25,734 | +41.56% | ||
| 2023-11-28 | Sale | Chevallard Daniel R. | CFO and COO | 3,720 0.0096% | $0.50 | $1,860 | +36.20% | |
| 2023-08-28 | Sale | Chevallard Daniel R. | CFO and COO | 3,512 0.0093% | $1.45 | $5,092 | -50.63% | |
| 2023-05-25 | Sale | Chevallard Daniel R. | CFO and COO | 3,635 0.0091% | $1.42 | $5,160 | -43.34% | |
| 2023-02-27 | Sale | Chevallard Daniel R. | CFO and COO | 3,599 0.0094% | $1.68 | $6,051 | -25.75% | |
| 2023-02-27 | Sale | Rojkjaer Lisa | Chief Medical Officer | 2,156 0.0056% | $1.68 | $3,625 | -25.75% | |
| 2022-11-28 | Sale | Chevallard Daniel R. | CFO and COO | 3,532 0.0101% | $2.72 | $9,606 | -42.66% | |
| 2022-11-28 | Sale | Rojkjaer Lisa | Chief Medical Officer | 2,116 0.006% | $2.72 | $5,754 | -42.66% | |
| 2022-08-25 | Sale | ROYSTON IVOR | CEO & President | 13,379 0.0334% | $4.01 | $53,656 | -59.98% | |
| 2022-08-25 | Sale | Chevallard Daniel R. | CFO and COO | 3,655 0.0091% | $4.02 | $14,679 | -59.98% | |
| 2022-08-25 | Sale | Rojkjaer Lisa | Chief Medical Officer | 2,190 0.0055% | $4.01 | $8,786 | -59.98% | |
| 2022-05-25 | Sale | ROYSTON IVOR | CEO & President | 13,162 0.0338% | $1.90 | $25,022 | +14.72% | |
| 2022-05-25 | Sale | Chevallard Daniel R. | CFO and COO | 3,596 0.0092% | $1.90 | $6,836 | +14.72% | |
| 2022-05-25 | Sale | Rojkjaer Lisa | Chief Medical Officer | 2,154 0.0055% | $1.90 | $4,095 | +14.72% | |
| 2022-02-28 | Sale | ROYSTON IVOR | CEO & President | 14,635 0.0397% | $2.78 | $40,678 | +6.23% | |
| 2022-02-28 | Sale | Chevallard Daniel R. | CFO and COO | 3,998 0.0108% | $2.78 | $11,112 | +6.23% | |
| 2022-02-28 | Sale | Rojkjaer Lisa | Chief Medical Officer | 2,395 0.0065% | $2.78 | $6,657 | +6.23% | |
| 2021-11-29 | Sale | ROYSTON IVOR | CEO & President | 15,833 0.0446% | $4.82 | $76,301 | -22.10% |
Insider Historical Profitability
| Rothera Mark | President and CEO | 100000 0.2589% | $0.56 | 2 | 0 | |
| Chevallard Daniel R. | CFO and COO | 102306 0.2559% | $0.56 | 0 | 11 | |
| ALTA BIOPHARMA PARTNERS III LP | 10910596 28.2478% | $0.56 | 2 | 1 | +23.63% | |
| Aisling Capital IV, LP | 10 percent owner | 10100000 26.1491% | $0.56 | 1 | 0 | <0.0001% |
| BAY CITY CAPITAL LLC | 10 percent owner | 5267598 13.6379% | $0.56 | 2 | 6 | +23.63% |
| DRANT RYAN D | 10 percent owner | 4659333 12.0631% | $0.56 | 2 | 5 | <0.0001% |
| BARRIS PETER J | 10 percent owner | 4659333 12.0631% | $0.56 | 0 | 5 | |
| BASKETT FOREST | 10 percent owner | 4659333 12.0631% | $0.56 | 2 | 5 | <0.0001% |
| BARRETT M JAMES | 10 percent owner | 4659333 12.0631% | $0.56 | 0 | 5 | |
| SANDELL SCOTT D | 10 percent owner | 4659333 12.0631% | $0.56 | 0 | 5 | |
| KERINS PATRICK J | 10 percent owner | 4659333 12.0631% | $0.56 | 2 | 5 | <0.0001% |
| KOLLURI KRISHNA KITTU | 10 percent owner | 4659333 12.0631% | $0.56 | 2 | 5 | <0.0001% |
| Growth Equity Opportunities Fund, LLC | 10 percent owner | 4659333 12.0631% | $0.56 | 2 | 5 | <0.0001% |
| LEFF JONATHAN S | director | 4304075 11.1434% | $0.56 | 2 | 0 | |
| Semon Dominique | 10 percent owner | 3921095 10.1518% | $0.56 | 0 | 3 | |
| MPM Oncology Impact Management GP LLC | 10 percent owner | 3331500 8.6253% | $0.56 | 3 | 0 | <0.0001% |
| WARBURG PINCUS EQUITY PARTNERS LP | 10 percent owner | 3204075 8.2954% | $0.56 | 2 | 7 | |
| Misfeldt Dayton | director | 1598260 4.1379% | $0.56 | 4 | 6 | +11.56% |
| LINEHAN CHARLES M | 10 percent owner | 999499 2.5877% | $0.56 | 1 | 0 | |
| TRAINOR III EUGENE A | 10 percent owner | 999499 2.5877% | $0.56 | 1 | 0 | |
| ROYSTON IVOR | CEO & President | 612770 1.5865% | $0.56 | 1 | 5 | <0.0001% |
| Wells James A | director | 318530 0.8247% | $0.56 | 0 | 1 | |
| Swisher Daniel N JR | President and CEO | 199736 0.5171% | $0.56 | 11 | 2 | +28.95% |
| EVNIN ANTHONY B | director | 133266 0.345% | $0.56 | 1 | 0 | |
| Quinn William P. | See Remarks | 127697 0.3306% | $0.56 | 3 | 0 | +12.95% |
| Ketchum Steven B | director | 80827 0.2093% | $0.56 | 3 | 3 | +23.63% |
| BJERKHOLT ERIC | EVP, CFO & Corp. Secretary | 80395 0.2081% | $0.56 | 5 | 2 | +21.5% |
| Rojkjaer Lisa | Chief Medical Officer | 48087 0.1245% | $0.56 | 0 | 7 | |
| Gullotta Tina | VP, Finance | 20500 0.0531% | $0.56 | 1 | 0 | <0.0001% |
| Parker Geoffrey M. | director | 14074 0.0364% | $0.56 | 5 | 0 | +13.76% |
| Craig Adam R | EVP, Development & CMO | 12723 0.0329% | $0.56 | 0 | 1 | |
| HURWITZ EDWARD | 0 0% | $0.56 | 1 | 1 | +62.16% |
Institutional Investor Ownership
| Bvf Inc Il | $3.69M | 9.2 | 3.61M | 0% | +$0 | 0.03 | |
| Citadel Advisors LLC | $1.6M | 3.99 | 1.57M | +2.36% | +$36,852.60 | <0.01 | |
| The Vanguard Group | $1.18M | 2.96 | 1.16M | 0% | +$0 | <0.0001 | |
| Samsara Biocapital Llc | $703,503.00 | 1.76 | 689,709 | 0% | +$0 | 0.11 | |
| Laurion Capital Management LP | $428,835.00 | 1.07 | 420,426 | -25.32% | -$145,420.54 | 0.01 | |
| MAI Capital Management, LLC | $371,379.00 | 0.93 | 364,097 | +2.43% | +$8,809.74 | <0.01 | |
| BlackRock | $310,060.00 | 0.77 | 303,980 | -0.55% | -$1,705.44 | <0.0001 | |
| Aisling Capital Management LP | $294,342.00 | 0.74 | 288,571 | 0% | +$0 | 0.1 | |
| Geode Capital Management | $257,826.00 | 0.64 | 252,701 | 0% | +$0 | <0.0001 | |
| Renaissance Technologies | $207,000.00 | 0.52 | 202,499 | +13.19% | +$24,124.56 | <0.0001 | |
| Morgan Stanley | $120,377.00 | 0.3 | 118,016 | +35.12% | +$31,288.68 | <0.0001 | |
| Bridgeway Capital Management | $75,480.00 | 0.19 | 74,000 | 0% | +$0 | <0.01 | |
| State Street | $67,184.00 | 0.17 | 65,867 | 0% | +$0 | <0.0001 | |
| Ensign Peak Advisors Inc | $64,674.00 | 0.16 | 63,406 | 0% | +$0 | <0.0001 | |
| Northern Trust | $38,954.00 | 0.1 | 38,190 | +4.74% | +$1,763.59 | <0.0001 | |
| UNITED BANK | $25,704.00 | 0.06 | 25,200 | 0% | +$0 | <0.01 | |
| Beacon Pointe Advisors Llc | $17,850.00 | 0.05 | 17,500 | New | +$17,850.00 | <0.0001 | |
| Xtx Topco Ltd | $17,328.00 | 0.04 | 16,988 | +44.57% | +$5,341.81 | <0.01 | |
| Inspirion Wealth Advisors LLC | $15,300.00 | 0.04 | 15,000 | +50% | +$5,100.00 | <0.01 | |
| HoyleCohen Wealth Management | $14,280.00 | 0.04 | 14,000 | 0% | +$0 | <0.01 | |
| Trust Co Of Toledo Na Oh | $12,563.00 | 0.03 | 12,317 | 0% | +$0 | <0.01 | |
| Bank of America | $12,516.00 | 0.03 | 12,271 | +52.17% | +$4,291.00 | <0.0001 | |
| Wealthtrust Axiom Llc | $11,623.00 | 0.03 | 11,396 | New | +$11,623.00 | <0.01 | |
| Acadian Asset Management | $11,000.00 | 0.03 | 10,908 | -83.14% | -$54,235.61 | <0.0001 | |
| Tower Research Capital | $9,067.00 | 0.02 | 8,889 | -36.5% | -$5,211.31 | <0.0001 | |
| Simplex Trading Llc | $4,000.00 | 0.01 | 4,884 | New | +$4,000.00 | <0.0001 | |
| RP Management LLC | $3,774.00 | 0.01 | 3,700 | 0% | +$0 | <0.01 | |
| IAG Wealth Partners | $3,060.00 | 0.01 | 3,000 | 0% | +$0 | <0.01 | |
| Barclays | $3,000.00 | 0.01 | 2,668 | 0% | +$0 | <0.0001 | |
| Royal Bank of Canada | $2,000.00 | 0.01 | 2,068 | -80.31% | -$8,159.57 | <0.0001 | |
| JPMorgan Chase | $735.00 | <0.01 | 721 | 0% | +$0 | <0.0001 | |
| Indiana Trust Investment Management Co | $204.00 | <0.01 | 200 | 0% | +$0 | <0.0001 | |
| Wells Fargo | $392.00 | <0.01 | 385 | +0.79% | +$3.06 | <0.0001 | |
| Newedge Advisors Llc | $14.00 | <0.01 | 14 | 0% | +$0 | <0.0001 | |
| Addison Advisors Llc | $5.00 | <0.01 | 4 | 0% | +$0 | <0.0001 | |
| Qube Research & Technologies | $2.00 | <0.01 | 2 | 0% | +$0 | <0.0001 | |
| Parallel Advisors, LLC | $8.00 | <0.01 | 8 | 0% | +$0 | <0.0001 | |
| UBS | $97.00 | <0.01 | 95 | -99.94% | -$172,121.90 | <0.0001 |